Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Galena Biopharma GALE

"Galena Biopharma is a biopharmaceutical company. Its main activity is the development and commercialization of hematology and oncology therapies. Its pipeline includes products targeting hematology diseases, breast cancer, gastric cancer, and gynecological cancer. The company’s cancer immunotherapy consists of two areas: prevention of cancer reoccurrence and primary prevention of invasive... see more

NDAQ:GALE - Post Discussion

Galena Biopharma > GALENA'S DROPPING AND SHE AIN'T STOPPING !!
View:
Post by Highrider7 on Feb 14, 2014 11:43am

GALENA'S DROPPING AND SHE AIN'T STOPPING !!

Wow ... what a trading opportunity. Up and down like a yo-yo. Right now Galena is dropping and she ain't stopping. Down over another 20 % so far today. Broke down through the $ 3.85 ( approx. ) holding level and the next holding level ( according to the chart ) is around the $ 2 - $ 2.50 level as seen below.



Galena Biopharma Inc

3.47USDDecrease0.885(-20.32%)Volume:
Above Average
As of 14 Feb 2014 at 11:34 AM EST.


Scale: 1d5d3m6m1y2y5y

Advanced Charts
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities